AIMS/HYPOTHESIS: Insulin resistance is associated with reduced serum adiponectin and increased albuminuria levels. Thus, one would anticipate an inverse relationship between circulating adiponectin and albuminuria. However, several studies have described a 'paradoxical' elevation of serum adiponectin in patients with elevated albuminuria. These findings may have been confounded by the presence of diseases and related treatments known to affect circulating adiponectin and albuminuria. We therefore studied the relationship between circulating adiponectin and albuminuria in the absence of such confounders. METHODS: To this purpose, the relationship between adiponectin isoforms and albumin:creatinine ratio (ACR) was investigated in a family-based sample of 634 non-diabetic untreated white individuals with normal kidney function. We also investigated whether the two variables share a common genetic background and addressed the specific role of the gene encoding adiponectin on that background by genotyping several ADIPOQ single nucleotide polymorphisms (SNPs). RESULTS: ACR was directly associated with high molecular weight (HMW) adiponectin isoform (p = 0.024). The two variables shared some genetic correlation (ρ(g) = 0.38, p = 0.04). ADIPOQ promoter SNP rs17300539 was associated with HMW adiponectin (p = 4.8 × 10(-5)) and ACR (p =0.0027). The genetic correlation between HMW adiponectin and ACR was no longer significant when SNP rs17300539 was added to the model, thus reinforcing the role of this SNP in determining both traits. CONCLUSIONS/ INTERPRETATION: Our study shows a positive, independent correlation between HWM adiponectin and ACR. ADIPOQ variability is associated with HMW adiponectin and ACR, and explains some of the common genetic background shared by these traits, thus suggesting that ADIPOQ and HMW adiponectin modulate albuminuria levels.
AIMS/HYPOTHESIS: Insulin resistance is associated with reduced serum adiponectin and increased albuminuria levels. Thus, one would anticipate an inverse relationship between circulating adiponectin and albuminuria. However, several studies have described a 'paradoxical' elevation of serum adiponectin in patients with elevated albuminuria. These findings may have been confounded by the presence of diseases and related treatments known to affect circulating adiponectin and albuminuria. We therefore studied the relationship between circulating adiponectin and albuminuria in the absence of such confounders. METHODS: To this purpose, the relationship between adiponectin isoforms and albumin:creatinine ratio (ACR) was investigated in a family-based sample of 634 non-diabetic untreated white individuals with normal kidney function. We also investigated whether the two variables share a common genetic background and addressed the specific role of the gene encoding adiponectin on that background by genotyping several ADIPOQ single nucleotide polymorphisms (SNPs). RESULTS:ACR was directly associated with high molecular weight (HMW) adiponectin isoform (p = 0.024). The two variables shared some genetic correlation (ρ(g) = 0.38, p = 0.04). ADIPOQ promoter SNP rs17300539 was associated with HMW adiponectin (p = 4.8 × 10(-5)) and ACR (p =0.0027). The genetic correlation between HMW adiponectin and ACR was no longer significant when SNP rs17300539 was added to the model, thus reinforcing the role of this SNP in determining both traits. CONCLUSIONS/ INTERPRETATION: Our study shows a positive, independent correlation between HWM adiponectin and ACR. ADIPOQ variability is associated with HMW adiponectin and ACR, and explains some of the common genetic background shared by these traits, thus suggesting that ADIPOQ and HMW adiponectin modulate albuminuria levels.
Authors: Giovanni F M Strippoli; Sankar D Navaneethan; David W Johnson; Vlado Perkovic; Fabio Pellegrini; Antonio Nicolucci; Jonathan C Craig Journal: BMJ Date: 2008-02-25
Authors: Pantelis A Sarafidis; Panagiotis C Stafylas; Panagiotis I Georgianos; Athanasios N Saratzis; Anastasios N Lasaridis Journal: Am J Kidney Dis Date: 2010-01-29 Impact factor: 8.860
Authors: Iris M Heid; Peter Henneman; Andrew Hicks; Stefan Coassin; Thomas Winkler; Yurii S Aulchenko; Christian Fuchsberger; Kijoung Song; Marie-France Hivert; Dawn M Waterworth; Nicholas J Timpson; J Brent Richards; John R B Perry; Toshiko Tanaka; Najaf Amin; Barbara Kollerits; Irene Pichler; Ben A Oostra; Barbara Thorand; Rune R Frants; Thomas Illig; Josée Dupuis; Beate Glaser; Tim Spector; Jack Guralnik; Josephine M Egan; Jose C Florez; David M Evans; Nicole Soranzo; Stefania Bandinelli; Olga D Carlson; Timothy M Frayling; Keith Burling; George Davey Smith; Vincent Mooser; Luigi Ferrucci; James B Meigs; Peter Vollenweider; Ko Willems van Dijk; Peter Pramstaller; Florian Kronenberg; Cornelia M van Duijn Journal: Atherosclerosis Date: 2009-12-02 Impact factor: 5.162
Authors: Christin Heidemann; Qi Sun; Rob M van Dam; James B Meigs; Cuilin Zhang; Shelley S Tworoger; Christos S Mantzoros; Frank B Hu Journal: Ann Intern Med Date: 2008-09-02 Impact factor: 25.391
Authors: Joachim Spranger; Anja Kroke; Matthias Möhlig; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer Journal: Lancet Date: 2003-01-18 Impact factor: 79.321
Authors: He Gao; Tove Fall; Rob M van Dam; Allan Flyvbjerg; Björn Zethelius; Erik Ingelsson; Sara Hägg Journal: Diabetes Date: 2012-12-28 Impact factor: 9.461
Authors: Maria Carolina Borges; Aluísio J D Barros; Diana L Santos Ferreira; Juan Pablo Casas; Bernardo Lessa Horta; Mika Kivimaki; Meena Kumari; Usha Menon; Tom R Gaunt; Yoav Ben-Shlomo; Deise F Freitas; Isabel O Oliveira; Aleksandra Gentry-Maharaj; Evangelia Fourkala; Debbie A Lawlor; Aroon D Hingorani Journal: Circ Cardiovasc Genet Date: 2017-12
Authors: Kieren J Mather; Qing Pan; William C Knowler; Tohru Funahashi; George A Bray; Richard Arakaki; Bonita Falkner; Kumar Sharma; Barry J Goldstein Journal: PLoS One Date: 2015-08-27 Impact factor: 3.240